Polyrizon Ltd. reported results from a comparative study assessing the regional nasal deposition profile of its intranasal naloxone formulation versus a commercial reference product. Using a validated silicone nasal cast model with quantitative image analysis at the University of Parma’s Biopharmanet-TEC center, Polyrizon’s formulation showed 94.6% (±4.0%) deposition in the nasal vestibule and upper turbinate compared with 79.6% (±3.0%) for the reference product, and 5.4% deposition in the lower turbinate versus 20.4% for the reference. The results have already been presented in the company’s announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260812PRIMZONEFULLFEED9662052) on February 26, 2026, and is solely responsible for the information contained therein.